JP2015509707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509707A5 JP2015509707A5 JP2014553750A JP2014553750A JP2015509707A5 JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5 JP 2014553750 A JP2014553750 A JP 2014553750A JP 2014553750 A JP2014553750 A JP 2014553750A JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- polypeptide
- length
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 150000001413 amino acids Chemical class 0.000 claims description 72
- 230000002163 immunogen Effects 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 229920001184 polypeptide Polymers 0.000 claims 70
- 108091033319 polynucleotide Proteins 0.000 claims 32
- 102000040430 polynucleotide Human genes 0.000 claims 32
- 239000002157 polynucleotide Substances 0.000 claims 32
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 230000000798 anti-retroviral effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382031.8 | 2012-01-27 | ||
| EP12382031.8A EP2620446A1 (en) | 2012-01-27 | 2012-01-27 | Immunogens for HIV vaccination |
| PCT/EP2013/051596 WO2013110818A2 (en) | 2012-01-27 | 2013-01-28 | Immunogens for hiv vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Division JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509707A JP2015509707A (ja) | 2015-04-02 |
| JP2015509707A5 true JP2015509707A5 (enExample) | 2016-03-17 |
| JP6306514B2 JP6306514B2 (ja) | 2018-04-04 |
Family
ID=47603800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553750A Active JP6306514B2 (ja) | 2012-01-27 | 2013-01-28 | Ｈｉｖワクチン接種のための免疫原 |
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9988425B2 (enExample) |
| EP (3) | EP2620446A1 (enExample) |
| JP (2) | JP6306514B2 (enExample) |
| KR (2) | KR102140778B1 (enExample) |
| CN (2) | CN104080800B (enExample) |
| AU (2) | AU2013213564B2 (enExample) |
| BR (1) | BR112014018396B1 (enExample) |
| CA (1) | CA2862172C (enExample) |
| ES (1) | ES2932407T3 (enExample) |
| IL (2) | IL233771B (enExample) |
| IN (1) | IN2014DN06164A (enExample) |
| MX (2) | MX358711B (enExample) |
| NZ (3) | NZ734689A (enExample) |
| RU (2) | RU2721274C2 (enExample) |
| WO (1) | WO2013110818A2 (enExample) |
| ZA (1) | ZA201405204B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| CN107635579A (zh) * | 2014-03-21 | 2018-01-26 | 纽泰克温图斯公司 | 非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法 |
| TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体モジュレーターの固体形態 |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| US20220226459A1 (en) * | 2019-05-22 | 2022-07-21 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
| WO2021228816A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| EP4277652A1 (en) | 2021-01-14 | 2023-11-22 | Gilead Sciences, Inc. | Hiv vaccines and methods of using |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| EP4417974A1 (en) | 2023-02-17 | 2024-08-21 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Cd33 as a biomarker of hiv control |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US6610476B1 (en) | 1984-08-22 | 2003-08-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of HIV-1 DNA |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5976541A (en) | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
| US5081226A (en) | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| GB8918200D0 (en) | 1989-08-09 | 1989-09-20 | Medical Res Council | The peptide fragments of hiv |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US7319000B1 (en) | 1992-09-16 | 2008-01-15 | Board Of Regents, The University Of Texas System | Compositions and methods for eliciting immune or anti-infective responses |
| JPH08511007A (ja) | 1993-06-09 | 1996-11-19 | コノート ラボラトリーズ リミテッド | タンデム合成ｈｉｖ−１ペプチド |
| WO1996020013A1 (en) | 1994-12-24 | 1996-07-04 | Cambridge University Technical Services Limited | Improvements in or relating to endometrial function |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US6093400A (en) | 1996-08-09 | 2000-07-25 | Cel Sci Corporation | Modified HGP-30 peptides, conjugates, compositions and methods of use |
| AU731367B2 (en) | 1996-08-09 | 2001-03-29 | Viral Technologies, Inc. | HIV p-17 peptide fragment, compositions containing and methods for producing and using same |
| US6031647A (en) | 1996-10-23 | 2000-02-29 | Nortel Networks Corporation | Stable power control for optical transmission systems |
| US5972339A (en) | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
| US20040106136A1 (en) | 1999-01-25 | 2004-06-03 | Musc Foundation For Research Development | Method for testing drug susceptibility of HIV |
| CN1297932A (zh) * | 1999-11-30 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸 |
| WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
| FR2803307A1 (fr) | 1999-12-30 | 2001-07-06 | Centre Nat Rech Scient | Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo |
| US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| CN1312275A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸 |
| JP2003531865A (ja) | 2000-04-28 | 2003-10-28 | アメリカ合衆国 | Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善 |
| EP1156112B1 (en) | 2000-05-18 | 2006-03-01 | Geneart GmbH | Synthetic gagpol genes and their uses |
| AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| CA2419822C (en) | 2000-08-14 | 2011-02-08 | Gary J. Nabel | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
| CU23235A1 (es) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| MXPA04002631A (es) | 2001-09-20 | 2004-07-08 | Glaxo Group Ltd | Vacunas de adn optimizadas por codon gag-vih. |
| AUPR842501A0 (en) | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| JP2005533752A (ja) | 2002-03-19 | 2005-11-10 | パウダーメド リミテッド | Ｈｉｖｄｎａワクチン接種におけるアジュバントとしてのイミダゾキノリンアミン |
| RU2238946C2 (ru) * | 2002-04-22 | 2004-10-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci |
| PL218318B1 (pl) | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| KR20100063126A (ko) | 2002-05-16 | 2010-06-10 | 버베리안 노딕 에이/에스 | Ｈｉｖ 조절/부속 단백질의 융합 단백질 |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| AU2003245729A1 (en) | 2002-06-27 | 2004-01-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| US20070248584A1 (en) | 2003-06-10 | 2007-10-25 | The University Of Melbourne | Immunomodulating Compositions, Uses Therefore and Processes for Their Production |
| BRPI0414443A (pt) | 2003-09-17 | 2006-11-21 | Univ Duke | imunógenos consensuais/ancestrais |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2005030964A1 (en) * | 2003-09-24 | 2005-04-07 | Oxxon Therapeutics Limited | Hiv pharmaccines |
| GB0323840D0 (en) | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
| WO2005047483A2 (en) | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
| US20090169503A1 (en) * | 2004-07-09 | 2009-07-02 | The Government Of The United States, As Represented By The Secretary Of Dept Of H&Hs | Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| ES2539010T3 (es) | 2004-08-27 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C |
| US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
| US20060095241A1 (en) | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US20060160070A1 (en) | 2004-10-29 | 2006-07-20 | Microsoft Corporation | Association-based epitome design |
| CA2597511A1 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
| US20100034840A1 (en) * | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| BRPI0504117A (pt) | 2005-09-05 | 2007-05-22 | Fundacao De Amparo A Pesquisa | epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção |
| PL2392587T3 (pl) | 2006-03-10 | 2016-08-31 | Peptcell Ltd | Sekwencje i kompozycje peptydów |
| GB0608368D0 (en) | 2006-04-28 | 2006-06-07 | Isis Innovation | Process for making Oligopeptides |
| EP2023954B1 (en) | 2006-05-19 | 2013-07-17 | Sanofi Pasteur, Inc. | Immunological composition |
| WO2008142479A2 (en) | 2006-08-25 | 2008-11-27 | The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
| US8198082B2 (en) | 2007-03-28 | 2012-06-12 | Hiroshima University | Method of determining chicken embryonic stem cells |
| EP2147121B1 (en) * | 2007-04-26 | 2014-12-17 | Merck Sharp & Dohme Corp. | Synthetic expression vectors for insect cells |
| WO2009009743A2 (en) * | 2007-07-12 | 2009-01-15 | Institute For Advance Study | Sequence optimization for expression of a foreign gene |
| WO2009089568A1 (en) | 2008-01-16 | 2009-07-23 | Opal Therapeutics Pty Ltd | Immunomodulating compositions and uses therefor |
| KR20110036618A (ko) | 2008-07-16 | 2011-04-07 | 베일러 리서치 인스티튜트 | 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신 |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8709775B2 (en) | 2008-08-29 | 2014-04-29 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| NZ593598A (en) * | 2008-11-18 | 2013-02-22 | Beth Israel Hospital | Optimized antiviral vaccines with improved cellular immunogenicity |
| AU2010295497B2 (en) | 2009-09-17 | 2014-10-09 | Global Solutions For Infectious Diseases | Immunological compositions for HIV |
| KR20120093941A (ko) | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| AU2010306559B2 (en) | 2009-10-16 | 2015-07-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . | Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites |
| WO2011082422A2 (en) | 2010-01-04 | 2011-07-07 | The Johns Hopkins University | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications |
| CA2817418A1 (en) | 2010-11-10 | 2012-05-18 | Laboratorios Del Dr. Esteve, S.A. | Highly immunogenic hiv p24 sequences |
| EP2620446A1 (en) * | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
| US20220226459A1 (en) | 2019-05-22 | 2022-07-21 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
-
2012
- 2012-01-27 EP EP12382031.8A patent/EP2620446A1/en not_active Withdrawn
-
2013
- 2013-01-28 MX MX2014009091A patent/MX358711B/es active IP Right Grant
- 2013-01-28 EP EP13701288.6A patent/EP2807185B1/en active Active
- 2013-01-28 JP JP2014553750A patent/JP6306514B2/ja active Active
- 2013-01-28 ES ES13701288T patent/ES2932407T3/es active Active
- 2013-01-28 CN CN201380006995.6A patent/CN104080800B/zh active Active
- 2013-01-28 KR KR1020197018840A patent/KR102140778B1/ko active Active
- 2013-01-28 IN IN6164DEN2014 patent/IN2014DN06164A/en unknown
- 2013-01-28 EP EP22195110.6A patent/EP4163290A1/en active Pending
- 2013-01-28 KR KR1020147023946A patent/KR102108149B1/ko active Active
- 2013-01-28 RU RU2018104969A patent/RU2721274C2/ru active
- 2013-01-28 NZ NZ734689A patent/NZ734689A/en unknown
- 2013-01-28 CA CA2862172A patent/CA2862172C/en active Active
- 2013-01-28 RU RU2014135053A patent/RU2648791C2/ru active
- 2013-01-28 WO PCT/EP2013/051596 patent/WO2013110818A2/en not_active Ceased
- 2013-01-28 AU AU2013213564A patent/AU2013213564B2/en active Active
- 2013-01-28 CN CN201910705866.5A patent/CN110372798A/zh active Pending
- 2013-01-28 NZ NZ723229A patent/NZ723229A/en unknown
- 2013-01-28 US US14/374,334 patent/US9988425B2/en active Active
- 2013-01-28 BR BR112014018396-1A patent/BR112014018396B1/pt active IP Right Grant
- 2013-01-28 NZ NZ628756A patent/NZ628756A/en unknown
-
2014
- 2014-07-16 ZA ZA2014/05204A patent/ZA201405204B/en unknown
- 2014-07-23 IL IL233771A patent/IL233771B/en active IP Right Grant
- 2014-07-25 MX MX2018010483A patent/MX2018010483A/es unknown
-
2017
- 2017-09-28 US US15/718,635 patent/US10815278B2/en active Active
-
2018
- 2018-03-08 JP JP2018041572A patent/JP6749357B2/ja active Active
- 2018-05-03 US US15/970,216 patent/US11325946B2/en active Active
- 2018-05-10 AU AU2018203264A patent/AU2018203264B2/en active Active
-
2019
- 2019-08-11 IL IL268629A patent/IL268629B/en active IP Right Grant
-
2021
- 2021-04-29 US US17/244,042 patent/US11919926B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162907B2 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| CN104884082B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| JP2008529558A5 (enExample) | ||
| JP2016533332A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| JP2018512856A5 (enExample) | ||
| BR112020022393A2 (pt) | composição, vacina compreendendo uma composição, método para produzir uma composição, molécula de ácido nucleico, e, vetor, célula hospedeira, kit compreendendo uma composição, e, vacinas para uso na profilaxia e/ou tratamento de infecção por citomegalovírus e por vírus sincicial respiratório. | |
| JP2012501959A5 (enExample) | ||
| US9388225B2 (en) | Modified coiled coil type proteins having improved properties | |
| JP2013532971A5 (enExample) | ||
| JP2013501038A5 (enExample) | ||
| JP2013507907A5 (enExample) | ||
| CN105960412A (zh) | 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒 | |
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| TW200844230A (en) | Signaling peptides | |
| CN117279659A (zh) | 人偏肺病毒疫苗 | |
| JP2016508143A5 (enExample) | ||
| JP2012516140A5 (enExample) | ||
| JP2024522385A5 (enExample) | ||
| JP2014504297A5 (enExample) | ||
| JP2016520534A5 (enExample) | ||
| ES2713962T3 (es) | Vacuna para prevenir la enfermedad de edema porcino | |
| JP2020509770A5 (enExample) |